Adriana Scheliga

4.8k total citations
20 papers, 490 citations indexed

About

Adriana Scheliga is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Adriana Scheliga has authored 20 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pathology and Forensic Medicine, 12 papers in Oncology and 7 papers in Genetics. Recurrent topics in Adriana Scheliga's work include Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (7 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Adriana Scheliga is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Viral-associated cancers and disorders (7 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Adriana Scheliga collaborates with scholars based in Brazil, Czechia and Italy. Adriana Scheliga's co-authors include Nelson Spector, José Carlos Morais, Irène Biasoli, Andréa Soares, Ofer Shpilberg, Pier Luigi Zinzani, Jan Walewski, Guilherme Loureiro Werneck, Ruth Pettengell and Michael Pfreundschuh and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and The Lancet Oncology.

In The Last Decade

Adriana Scheliga

20 papers receiving 478 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adriana Scheliga Brazil	12	319	252	117	101	55	20	490
Anca Prica Canada	14	234 0.7×	238 0.9×	147 1.3×	55 0.5×	119 2.2×	130	609
Wendy B.C. Stevens Netherlands	12	311 1.0×	202 0.8×	195 1.7×	190 1.9×	38 0.7×	27	520
Cécile Borel France	13	130 0.4×	170 0.7×	101 0.9×	98 1.0×	74 1.3×	48	580
Stefanie Kreissl Germany	14	390 1.2×	303 1.2×	51 0.4×	150 1.5×	16 0.3×	31	567
José Carlos Morais Brazil	13	232 0.7×	224 0.9×	87 0.7×	31 0.3×	59 1.1×	37	468
Nancy Eby United States	10	358 1.1×	246 1.0×	220 1.9×	300 3.0×	48 0.9×	15	772
Yi‐Bin Chen United States	9	126 0.4×	172 0.7×	45 0.4×	58 0.6×	34 0.6×	12	308
Teresa Halbsguth Germany	15	485 1.5×	443 1.8×	85 0.7×	179 1.8×	53 1.0×	25	971
Indra Thielen Germany	7	218 0.7×	202 0.8×	44 0.4×	61 0.6×	28 0.5×	9	438
A. Contu Italy	18	222 0.7×	486 1.9×	60 0.5×	71 0.7×	119 2.2×	51	802

Countries citing papers authored by Adriana Scheliga

Since Specialization

Citations

This map shows the geographic impact of Adriana Scheliga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adriana Scheliga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adriana Scheliga more than expected).

Fields of papers citing papers by Adriana Scheliga

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adriana Scheliga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adriana Scheliga. The network helps show where Adriana Scheliga may publish in the future.

Co-authorship network of co-authors of Adriana Scheliga

This figure shows the co-authorship network connecting the top 25 collaborators of Adriana Scheliga. A scholar is included among the top collaborators of Adriana Scheliga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adriana Scheliga. Adriana Scheliga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leonard, John P., Marek Trněný, Koji Izutsu, et al.. (2019). AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R²) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. Hematological Oncology. 37(S2). 114–115. 8 indexed citations

Gribben, John G., Marek Trněný, Koji Izutsu, et al.. (2019). AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R²) THAN RITUXIMAB/PLACEBO. Hematological Oncology. 37(S2). 227–229. 1 indexed citations

Soares, Andréa, Irène Biasoli, Adriana Scheliga, et al.. (2013). Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma. Supportive Care in Cancer. 21(8). 2153–2159. 37 indexed citations

Biasoli, Irène, Adriana Scheliga, Andréa Soares, et al.. (2012). Psychometric Properties of the Multidimensional Fatigue Inventory in Brazilian Hodgkin's Lymphoma Survivors. Journal of Pain and Symptom Management. 44(6). 908–915. 25 indexed citations

Crump, M., Adriana Scheliga, Jiří Mayer, et al.. (2011). Efficacy and safety of bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed, R-naive/-sensitive follicular lymphoma (FL): outcome according to prior therapy. Annals of Oncology. 22. 186–186. 1 indexed citations

Kimby, Eva, Adriana Scheliga, Jiří Mayer, et al.. (2011). FCGR3A polymorphism does not significantly affect response and outcome of follicular lymphoma patients treated in the PRIMA study with rituximab and chemotherapy followed by rituximab maintenance or observation. Annals of Oncology. 22. 187–187. 1 indexed citations

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2011). Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. The Lancet Oncology. 12(8). 773–784. 81 indexed citations

Soares, Andréa, Irène Biasoli, Adriana Scheliga, et al.. (2011). Validation of the Brazilian Portuguese version of the Medical Outcomes Study-Social Support Survey in Hodgkin's lymphoma survivors. Supportive Care in Cancer. 20(8). 1895–1900. 29 indexed citations

Barros, Mário Henrique M., Adriana Scheliga, Elena De Matteo, et al.. (2010). Cell cycle characteristics and Epstein–Barr virus are differentially associated with aggressive and non-aggressive subsets of Hodgkin lymphoma in pediatric patients. Leukemia & lymphoma. 51(8). 1513–1526. 16 indexed citations

10.

Biasoli, Irène, Adriana Scheliga, Andréa Soares, et al.. (2010). Advanced Hodgkin's lymphoma: results in 216 patients treated with ABVD in Brazil. Revista Brasileira de Hematologia e Hemoterapia. 32(4). 303–307. 2 indexed citations

11.

Coiffier, Bertrand, Evgenii A. Osmanov, Xiaonan Hong, et al.. (2010). A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. Blood. 116(21). 857–857. 11 indexed citations

12.

Lossos, Izidore S., Irène Biasoli, José Carlos Morais, et al.. (2009). Human germinal center-associated lymphoma protein expression is associated with improved failure-free survival in Brazilian patients with classical Hodgkin lymphoma. Leukemia & lymphoma. 50(11). 1830–1836. 12 indexed citations

13.

Biasoli, Irène, Rony Schaffel, Cristiane Milito, et al.. (2008). Evaluation of intra‐ and interobserver agreement and its clinical significance for scoring bcl‐2 immunohistochemical expression in diffuse large B‐cell lymphoma. Pathology International. 58(9). 596–600. 12 indexed citations

14.

Pfreundschuh, Michael, Anthony D. Ho, Eva Cavallin‐Ståhl, et al.. (2008). Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. The Lancet Oncology. 9(5). 435–444. 154 indexed citations

15.

Araujo, Luiz H., Ana Paula Victorino, Andréia Cristina de Melo, et al.. (2008). Linfoma Não-Hodgkin de Alto Grau - Revisão da Literatura. SHILAP Revista de lepidopterología. 54(2). 175–183. 2 indexed citations

16.

Schaffel, Rony, José Carlos Morais, Irène Biasoli, et al.. (2007). PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma. Modern Pathology. 20(3). 326–330. 20 indexed citations

17.

Soares, Andréa, Irène Biasoli, Adriana Scheliga, et al.. (2006). Socioeconomic inequality and short‐term outcome in Hodgkin's lymphoma. International Journal of Cancer. 120(4). 875–879. 20 indexed citations

18.

Carvalho, Maria da Glória, et al.. (2006). Detection of free circulating Epstein-Barr virus DNA in plasma of patients with Hodgkin’s disease. Sao Paulo Medical Journal. 124(3). 154–157. 25 indexed citations

19.

Biasoli, Irène, José Carlos Morais, Adriana Scheliga, et al.. (2005). CD10 and Bcl‐2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large‐cell lymphoma with very good or very poor prognoses. Histopathology. 46(3). 328–333. 32 indexed citations

20.

Schaffel, Rony, Irène Biasoli, Adriana Scheliga, et al.. (2004). The Expression of Protein Kinase C Beta II (PKCβ) by Immunocytochemistry Is Predictive of the Disease Free Survival (DFS) in Diffuse Large B-Cell Lymphoma (DLBCL).. Blood. 104(11). 4561–4561. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact